Top Markets
#1 Islamic Coin Islamic Coin +151.55%
#2 Black Phoenix Black Phoenix +25.61%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.62%
#4 Fake World Assets Fake World Assets +16.15%
#5 Akedo Akedo +12.71%
#6 OpenEden OpenEden +12.39%
#7 clBTC clBTC +11.98%
#8 Palladium Network Palladium Network +11.96%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.81%
#10 Pons Pons +11.07%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Classement en actions #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Prix de l'action
$0.00366968
Dernière synchronisation: 2024-07-23
Capitalisation boursière
$291.42K
Changement (1 jour)
-0.81%
Changement (1 an)
0.00%
Pays
US
Échange Bioasis Technologies Inc. (BTI)

Catégorie

Healthcare
Revenus pour Bioasis Technologies Inc. (BTI)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Bioasis Technologies Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Bioasis Technologies Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE